EP3525754A1 - Method for producing dermatological and cosmetic preparations - Google Patents
Method for producing dermatological and cosmetic preparationsInfo
- Publication number
- EP3525754A1 EP3525754A1 EP17798315.2A EP17798315A EP3525754A1 EP 3525754 A1 EP3525754 A1 EP 3525754A1 EP 17798315 A EP17798315 A EP 17798315A EP 3525754 A1 EP3525754 A1 EP 3525754A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formulation
- proportion
- added
- ultrasonic waves
- emulsion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000002537 cosmetic Substances 0.000 title claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 11
- 239000008350 hydrogenated phosphatidyl choline Substances 0.000 claims abstract description 11
- 150000008105 phosphatidylcholines Chemical class 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 19
- 239000000839 emulsion Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 7
- 229940043375 1,5-pentanediol Drugs 0.000 claims description 5
- 150000002632 lipids Chemical group 0.000 claims description 5
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000012503 blood component Substances 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229940035674 anesthetics Drugs 0.000 claims 1
- 230000001857 anti-mycotic effect Effects 0.000 claims 1
- 230000002421 anti-septic effect Effects 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000002543 antimycotic Substances 0.000 claims 1
- 229940064004 antiseptic throat preparations Drugs 0.000 claims 1
- 239000003212 astringent agent Substances 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 229960001631 carbomer Drugs 0.000 claims 1
- 239000001913 cellulose Chemical class 0.000 claims 1
- 229920002678 cellulose Chemical class 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- 239000003925 fat Substances 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 239000000416 hydrocolloid Substances 0.000 claims 1
- 235000019426 modified starch Nutrition 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 235000019871 vegetable fat Nutrition 0.000 claims 1
- 235000013311 vegetables Nutrition 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- 239000006071 cream Substances 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 241000195493 Cryptophyta Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 229940057917 medium chain triglycerides Drugs 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000036572 transepidermal water loss Effects 0.000 description 3
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- -1 pentylene, butylene Chemical group 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000008384 inner phase Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N n-propyl alcohol Natural products CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000008385 outer phase Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037204 skin physiology Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0204—Specific forms not provided for by any of groups A61K8/0208 - A61K8/14
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/82—Preparation or application process involves sonication or ultrasonication
Definitions
- the present invention relates to a process for the preparation of dermatological and cosmetic preparations with pronounced lamellar structures using hydrogenated phosphatidylcholine.
- DMS Dermata Membrane Structure
- the lamellar structures correspond to the skin physiology and serve the skin to protect against the ingress of external substances and regulate the transepidermal water loss through the skin.
- lamellar structures The formation of the lamellar structures is dependent on the geometric packing factors, such as the volume of the fatty acid chains, the critical chain length, and area occupied by the headgroup (Israelachvili, JN In Intermolecular and Surface Forces, 2nd Ed., Jovanovich, HB; London 1994). This means that not every amphiphilic substance can form lamellar structures or membranes.
- the best-known lipid capable of forming such lamellar structures is phosphatidylcholine (PC), also part of human cell membranes. Phosphatidylcholine is found in a high concentration in soya lecithin.
- phosphatidylcholine especially the hydrogenated one, shows a pronounced barrier-stabilizing effect.
- the skin barrier is stabilized by PCH-containing preparations with lamellar structure in such a way that after application of the transepidermal water loss (TEWL) changes only slightly when external substances act on the skin.
- TEWL transepidermal water loss
- the protection thus obtained is also characterized by a high water resistance and welding strength.
- the use of hydrogenated phosphatidylcholine is highly desirable for cosmetic or dermatological preparations.
- the object of this invention was to develop a method with which it is possible, using the known since 1995 ingredients for membrane structure creams, in particular using hydrogenated phosphatidylcholine, stable cream bases for topical application to produce a qualitatively and quantitatively pronounced lamellar Have structure and in which active ingredients and biological materials at room temperature, in one operation open-minded (ie detached from their cells and agglomerates split) and can be stored directly between the forming lamellar structures.
- Another important advantage of the inventive production process is the possibility of producing very small units of 20-50 ml with individual formulations adapted to the skin type.
- Galenic preparations for cosmetic or dermatological products consist predominantly of a water phase and a fat phase. Both phases are usually mixed or emulsified with the aid of appropriate emulsifiers and with the use of high-speed stirrers, mixers or the like.
- the inner phase is distributed as finely as possible in the outer phase, so that a sufficient stability and storage time is achieved.
- a sufficient amount of emulsifiers and preservatives is also necessary to ensure a practical storage time of the products.
- Emulsifiers and preservatives are, however, substances which pollute the skin and are often triggers of allergies.
- a cosmetic or dermatological preparation can be produced in less than one minute, without chemical emulsifiers and at room temperature, even using temperature-sensitive, biological materials .
- preemulsions can also be used, which are then mixed in a second step at any later time with additional dermatological and / or cosmetic agents, for example with biological cell materials, blood components such as blood plasma or blood serum, vegetable oils, vitamins, peptides , Hyaluronic acids, plant extracts, fruit acids and the like.
- the ultrasound introduction described above can already take place during the production of the pre-emulsion and / or after the addition of the additives in a second operation.
- the introduction of the ultrasound in the pre-emulsion has the purpose of hydrogenating with the aid of the present Membraniipide, preferably phosphatidylcholine and / or not hydrogenated to produce fine oil droplets in the range of 5-500nm, preferably in a size of 50-250 nm, which then in the described second step, in the introduction of the additives, form particularly fine lamellar layers.
- the aid of the present Membraniipide preferably phosphatidylcholine and / or not hydrogenated to produce fine oil droplets in the range of 5-500nm, preferably in a size of 50-250 nm, which then in the described second step, in the introduction of the additives, form particularly fine lamellar layers.
- the monohydric and / or polyhydric alcohols are preferably methyl, ethyl, propyl or isopropyl alcohol, phenoxyethanol, pentylene, butylene or hexylene glycol. definitions
- Ultrasound machines are available in different designs and services.
- devices are needed which provide sufficient energy needed to disperse a liquid phase (fat phase) into small drops in a second phase (stable phase).
- imploding cavitation bubbles cause intense shockwaves in the liquid and as a result, generate very high velocity liquid jets.
- the newly formed droplets of the dispersed phase align themselves immediately with the help of the membrane lipids and form lamellar structures with a thickness of a few nanometers, with the lipophilic phases and the hydrophilic phases then alternatingly stacking up.
- the vibration amplitudes of the introduced ultrasound preferably move from about 1 to 200 microns, while the high pressure and low pressure cycles between 15,000-30,000 cycles / sec, preferably at 20,000 cycles / sec. be.
- the shear forces mechanically close the cell envelope and thereby increase the exchange of material.
- the membrane lipids hydrogenated phosphatidylcholine
- the lamellar layers in which the intracellular material is spontaneously incorporated are formed.
- Organic cell material in this patent means materials which have been dissolved out of biological cells. These may be of plant origin, e.g. Algae and / or animal or human origin. They may be derived from tissues and / or body fluids such as blood and / or from microorganisms such as yeasts or bacteria.
- MS concentrate prepared with hydrogenated phosphatidylcholine, neutral oil and homogenized via a high-pressure homogenizer
- neutral oil medium-chain triglycerides
- the components are placed in a glass container, which is closed and placed in the ultrasound machine, which introduces the ultrasound from the outside through the wall. After just one minute, the formation of a homogeneous cream mass is evident.
- the components are placed in a glass container, which is closed and placed in the ultrasound machine, which introduces the ultrasound from the outside through the wall. After just one minute, the formation of a homogeneous cream mass is evident.
- the components of the pre-emulsion are heated to 70 ° C and charged with ultrasound until a homogeneous milk is formed with a droplet size of 50-200 nm.
- This pre-emulsion can be stored under exclusion of air for several months.
- the components are mixed, resulting in the formation of fine, lamellar layer structures directly from the nanoparticles of the pre-emulsion, which is indicated by a significant increase in viscosity, while the added active ingredients, such as oils, blood components and hyaluronic acid intercalate between the lamellar layers.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH01356/16A CH713023A2 (en) | 2016-10-11 | 2016-10-11 | Process for the preparation of dermatological and cosmetic preparations with pronounced lamellar structures using phosphatidylcholine and biological cell materials, which are disrupted by the action of ultrasonic waves and at the same time embedded between the lamellar structures. |
PCT/IB2017/056221 WO2018069814A1 (en) | 2016-10-11 | 2017-10-09 | Method for producing dermatological and cosmetic preparations |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3525754A1 true EP3525754A1 (en) | 2019-08-21 |
Family
ID=60331675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17798315.2A Pending EP3525754A1 (en) | 2016-10-11 | 2017-10-09 | Method for producing dermatological and cosmetic preparations |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3525754A1 (en) |
CH (1) | CH713023A2 (en) |
WO (1) | WO2018069814A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH714305B1 (en) * | 2017-11-06 | 2022-07-15 | Cosmetolab Ag | Process for preparing topical formulations and prepared formulations. |
CN112512484A (en) | 2018-08-08 | 2021-03-16 | 苏比品牌公司 | Cosmetic base composition and related cosmetic composition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4221255C2 (en) * | 1992-06-26 | 1994-09-15 | Lancaster Group Ag | Cosmetolipid-containing cosmetic |
DE4327679A1 (en) * | 1993-08-13 | 1995-02-16 | Lancaster Group Ag | Functional oxygenated preparation |
DE4447287C1 (en) * | 1994-12-30 | 1996-11-07 | Cevc Gregor | Droplet-in-fluid composition to transport agent e.g. through skin |
DE19857492A1 (en) | 1998-12-14 | 2000-06-15 | Hans Lautenschlaeger | Cosmetic or dermatological skin-protective compositions, containing saturated phosphatidyl choline to give good barrier stabilizing and active agent penetrating effects |
EP1259218B1 (en) | 2000-02-25 | 2010-05-26 | Kuhs GmbH | Cosmetic composition for the treatment of skin ageing and/or stressed skin |
DE102005011786A1 (en) * | 2005-03-11 | 2006-09-14 | Pharmasol Gmbh | Process for preparing ultrafine submicron suspensions |
DE102006015544A1 (en) | 2006-03-31 | 2007-10-04 | Kuhs Gmbh | Topical composition, useful for infants or baby e.g. to reduce skin roughness, comprises hydrophilic liquid, anti-inflammatory active agent and a carrier substance with hydrophilic liquid forming lamellar double-membrane layer |
PL2020221T3 (en) * | 2007-06-19 | 2012-07-31 | Neubourg Skin Care Gmbh & Co Kg | DMS (Derma Membrane Structure) in foaming creams |
EP2363108B1 (en) * | 2010-03-02 | 2017-08-30 | Neubourg Skin Care GmbH & Co. KG | Foam formulation containing at least one triterpenoid |
DE102011110749A1 (en) | 2011-08-16 | 2013-02-21 | Gabriele Blume | Cosmetic or pharmaceutical composition with lamellar structures using sucrose fatty triesters - simple and easy preparation |
-
2016
- 2016-10-11 CH CH01356/16A patent/CH713023A2/en not_active Application Discontinuation
-
2017
- 2017-10-09 WO PCT/IB2017/056221 patent/WO2018069814A1/en unknown
- 2017-10-09 EP EP17798315.2A patent/EP3525754A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018069814A1 (en) | 2018-04-19 |
CH713023A2 (en) | 2018-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2661108C2 (en) | Use of a liposome dispersion in cosmetics | |
EP2020221B1 (en) | DMS (Derma Membrane Structure) in foaming creams | |
DE3125710C2 (en) | ||
DE60130719T2 (en) | Foaming cosmetic cream for the treatment of oily skin | |
EP2363108B1 (en) | Foam formulation containing at least one triterpenoid | |
WO2007036376A2 (en) | Skincare products | |
WO2008138894A2 (en) | Surfactant-free foam formulations | |
DE3537723A1 (en) | COMPOSITION FOR COSMETIC OR PHARMACEUTICAL USE THAT CONTAINS NIOSOME AND AT LEAST A WATER-SOLUBLE POLYAMIDE, AND METHOD FOR PRODUCING THIS COMPOSITION | |
DE3713494A1 (en) | METHOD FOR PRODUCING A DISPERSION OF LIPID BALLS IN AN AQUEOUS PHASE AND DISPERSIONS AVAILABLE ACCORDING TO THIS METHOD | |
DE69828596T2 (en) | WAESSERIGE COMPOSITIONS CONTAINING A LIPIDIC AND A TENSID ON LANOLINBASIS AND ITS USE | |
EP0945136B9 (en) | Topical pharmaceutical preparation comprising ciclosporin | |
WO2012146576A1 (en) | Oil-in-water emulsion concentrate, method for producing same, and skin cosmetic containing said oil-in-water emulsion concentrate | |
EP3525754A1 (en) | Method for producing dermatological and cosmetic preparations | |
DE68915191T2 (en) | Use of polyacrylate polymers as stabilizers for suspensions, suspensions obtained from a water-insoluble phase in an aqueous phase and their preparation. | |
WO2017063748A1 (en) | Composition and method for producing dermatological and cosmetic preparations having pronounced lamellar structures using phosphatidycholine and fermentation by microorganisms | |
DE3815473A1 (en) | System of active substances for lipid exchange with target structures | |
JPS5939338A (en) | Emulsified composition | |
EP4284319A1 (en) | New foam formulations for dermatological application, with phase reversal | |
KR102199766B1 (en) | Manufacturing method of multi-lamellar structured transparent liquid crystal composition | |
DE10015463B4 (en) | Cream in the form of an overbased water-in-oil emulsion | |
CN117919115B (en) | Skin care type skin plastid, preparation method and application thereof in cosmetics | |
EP2768471B1 (en) | Aqueous dispersion having a content of lipid nanoparticles, process for production thereof and use thereof | |
AT361896B (en) | BALL DISPERSION AND METHOD FOR THE PRODUCTION THEREOF | |
DE19635359C2 (en) | Lotion for body care | |
WO2011147410A2 (en) | Method for producing a micellar active ingredient concentrate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190507 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200608 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MAUSER, JOHANNES ALOIS Owner name: KUHS, BERND ARIS |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KUHS, BERND ARIS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |